Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2CLIMB-05 maintenance tucatinib study in metastatic HER2-positive breast cancer
jRCT2011220007Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tucatinib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Apr 2022; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2011220007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220007.